Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention

Fineline Cube Apr 14, 2026
Company Drug

Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC

Fineline Cube Apr 14, 2026
Company Drug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

Fineline Cube Mar 7, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...

Company Drug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

Fineline Cube Mar 7, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...

Company Deals

4C Medical Lands $175M Series D to Advance AltaValve TMVR System

Fineline Cube Mar 7, 2025

US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech...

Company

Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences

Fineline Cube Mar 7, 2025

German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...

Company Deals

Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform

Fineline Cube Mar 7, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...

Company Drug

Johnson & Johnson Officially Launches Spravato in China for Depression Treatment

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...

Company Drug

Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA

Fineline Cube Mar 7, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Medical Device

Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market

Fineline Cube Mar 7, 2025

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement...

Company Deals Drug

Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)

Fineline Cube Mar 7, 2025

Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement...

Company Drug

Suzhou GenAssist’s GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment

Fineline Cube Mar 7, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced receiving clearance from the US Food and...

Company Drug

BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies

Fineline Cube Mar 7, 2025

Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...

Company Drug

CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced a Phase Ib clinical filing in Australia for...

Company Drug

Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment

Fineline Cube Mar 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment

Fineline Cube Mar 6, 2025

China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products...

Company Drug

CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced clinical approval from the National Medical...

Company

Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth

Fineline Cube Mar 6, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...

Company Medical Device

Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan

Fineline Cube Mar 6, 2025

China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries...

Company Medical Device

Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval

Fineline Cube Mar 6, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies

Fineline Cube Mar 6, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...

Posts pagination

1 … 185 186 187 … 650

Recent updates

  • WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment
  • Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring
  • Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization
  • Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention
  • Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Company Medical Device

Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring

Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Company Drug

Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.